What does Silo Pharma do?
Silo Pharma, Inc. is a Nasdaq Capital Market-listed developmental-stage company advancing treatments for stress-related psychiatric disorders, chronic pain, and central nervous system diseases. Its lead program is SPC-15, an intranasal candidate for post-traumatic stress disorder and stress-induced anxiety. The company’s 2025 Form 10-K also identifies SP-26 for fibromyalgia, SPC-14 for Alzheimer’s disease, and SPU-16 for multiple sclerosis research.
A biopharma platform with newer technology adjacencies
The pharmaceutical pipeline remains the central scientific story, but Silo is no longer a pure-play biotech. It acquired software associated with r2crypto.com in 2025 and QwikAgents software and domains in March 2026 for stock valued at $714,000. The official company overview now describes a diversified developmental-stage biopharma and cryptocurrency-treasury strategy, creating potential optionality but also a broader execution burden.
How does Silo Pharma make money?
Today, Silo does not earn meaningful commercial pharmaceutical revenue. The $18,026 reported for the quarter ended March 31, 2026 came from amortized license and sublicense consideration connected with the Aikido agreement, not product sales. Cost of revenue was $20,688, so the quarter produced a small gross loss of $2,662. The practical business model is therefore financed research: raise capital, license or acquire assets, fund preclinical and regulatory work, and seek value through eventual product commercialization, sublicensing, partnerships, or strategic transactions.
The economic engine is capital deployment, not present revenue
For a pre-commercial biotech, the most important “revenue stream” is often access to external capital. Silo raised net financing cash of $4.86 million in FY2025 and announced a July 2026 private placement with about $4 million of expected gross proceeds, plus up to approximately $7.7 million of potential warrant proceeds if investors exercise all warrants for cash. Those potential proceeds are conditional, so they should not be modeled as guaranteed liquidity. The financing terms are available in the company’s July 2026 securities purchase agreement.
| Economic pathway | Present status | Primary driver | Main constraint |
|---|---|---|---|
| Existing license revenue | $72,102 in FY2025 | Contractual revenue recognition | Too small to fund operations |
| Drug partnering | Potential, not established | Clinical evidence and intellectual-property rights | Development and regulatory risk |
| Commercial drug sales | No approved product | Approval, reimbursement, manufacturing, and market adoption | Long timeline and high capital need |
| QwikAgents subscriptions | Early commercialization stage | Customer acquisition and platform reliability | Crowded AI infrastructure market and limited disclosed traction |
Which drug programs matter most?
Silo’s four named therapeutic programs are not equally mature. SPC-15 is the lead asset because it has a defined intranasal formulation, exclusive global development rights from Columbia University, a completed FDA pre-IND interaction, and a stated path toward a first-in-human study. The company’s SPC-15 program page describes the candidate as a non-psychedelic 5-HT4 receptor agonist with biomarker-guided development and nose-to-brain delivery.
Why delivery technology is central to the thesis
Silo’s strategy is not simply to discover new molecules. It seeks to combine known or academically developed compounds with differentiated delivery approaches. SPC-15 uses a proprietary soft-mist nasal spray; SP-26 uses a subcutaneous dissolvable implant designed to regulate ketamine release. The SP-26 program page frames the implant as a non-opioid alternative with controlled dosing. If delivery improves exposure, safety, adherence, or regulatory efficiency, it could create licensing value. If not, Silo has limited scale or commercial infrastructure to fall back on.
What does Silo Pharma’s latest quarter show?
The quarter ended March 31, 2026 confirms that Silo remains a cash-consuming research platform rather than an operating pharmaceutical business. Revenue was unchanged year over year at $18,026, operating expenses rose 43.3% to $1.592 million, and net loss widened 59.7% to $1.647 million. Of Q1 R&D expense, $714,000 was non-cash stock consideration for QwikAgents, so accounting loss exceeded cash burn while equity financed the expansion beyond therapeutics.
Where did the quarter’s spending go?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $18,026 | $18,026 | No operating growth signal. |
| Gross profit (loss) | $(2,662) | $16,566 | Accelerated license-cost amortization pushed gross profit negative. |
| R&D expense | $1,013,265 | $593,962 | Up 70.6%; includes $714,000 of acquired software expensed immediately. |
| Loss from operations | $(1,594,660) | $(1,094,121) | Operating loss increased 45.7%. |
| Net loss | $(1,647,117) | $(1,031,437) | Wider loss also reflects crypto and investment-related losses. |
What turning points shaped Silo Pharma’s current strategy?
Silo’s history is a sequence of corporate pivots, academic licenses, financing events, and asset additions rather than a linear drug-development path. The relevant turning points explain why the company now combines preclinical therapeutics, delivery technology, software, and a crypto-treasury strategy.
-
2010The legal entity was incorporated in New York. This legacy corporate history predates the current therapeutic strategy.
-
2020The company adopted the Silo Pharma name and began operating under its current biopharmaceutical plan, making this the economically relevant starting point.
-
2021Licensing and research arrangements with the University of Maryland supported the SPU-16 concept and sublicensing economics.
-
2022SILO began trading on Nasdaq after a 1-for-50 reverse split, improving capital-market visibility but establishing a pattern of share-structure management.
-
2023–2024Medspray and Columbia agreements strengthened SPC-15’s formulation and exclusive-rights package; the FDA pre-IND process clarified the proposed 505(b)(2) pathway.
-
2025The company added crypto and web-software assets while continuing therapeutic research, broadening the corporate model beyond biotech.
-
2026Silo acquired QwikAgents, completed a 1-for-15 reverse split, regained Nasdaq bid-price compliance, and announced another private placement. These events made capital structure and strategic coherence central to the analysis.
Why the 2026 share events matter
The June 2026 reverse split reduced shares on a 1-for-15 basis and helped Silo regain Nasdaq minimum-bid compliance. Nasdaq later closed the matter after the stock maintained the required price from June 3 through June 16, 2026, according to the June 2026 Form 8-K. The episode matters because exchange compliance directly affects liquidity and financing access.
What gives Silo Pharma a competitive advantage?
Silo does not possess the scale, clinical infrastructure, commercial organization, or balance sheet of a large pharmaceutical company. Its prospective advantage is narrower: assemble exclusive academic rights, differentiated formulations, and potentially more efficient regulatory pathways around underserved indications. SPC-15’s combination of Columbia intellectual property, biomarker work, and Medspray delivery technology is the clearest example. SP-26 similarly attempts to differentiate ketamine through controlled-release implantation rather than through the molecule alone.
Who are the real competitors?
Competition should be defined by indication and development approach, not by market capitalization. For PTSD, Silo competes against approved generic therapies, psychotherapy, and other companies testing rapid-acting, psychedelic, or biomarker-guided treatments. For fibromyalgia, it competes against approved oral drugs, off-label pain regimens, device-based approaches, and emerging non-opioid therapies. In AI-agent hosting, it faces a separate set of cloud, software, and open-source competitors with stronger distribution and engineering resources.
How financially strong is Silo Pharma?
At March 31, 2026, Silo had $3.903 million of cash, $2.130 million of short-term investments, $6.804 million of current assets, and $704,845 of current liabilities, producing $6.099 million of working capital. Management said liquid resources were sufficient for at least twelve months from the May 13, 2026 filing date. The July private placement should extend runway, although exact post-closing liquidity awaits a later quarterly balance sheet.
Cash burn is lower than accounting loss, but still material
FY2025 operating cash use was $4.661 million, up 21.6% from $3.834 million in FY2024. Financing cash of $4.860 million was therefore essential. The financial loop is straightforward: research and corporate initiatives consume cash, while equity and warrant offerings replenish it and may dilute existing holders.
| Financial signal | FY2025 | Q1 2026 / March 31, 2026 | Analytical reading |
|---|---|---|---|
| Revenue | $72,102 | $18,026 | Minimal recurring license accounting, not commercial scale. |
| Net loss | $(4.228M) | $(1.647M) | Loss profile remains substantial relative to asset base. |
| Operating cash flow | $(4.661M) | $(0.823M) | Cash burn improved in Q1 versus the prior-year quarter, partly due to non-cash expense mix. |
| Working capital | $6.738M | $6.099M | Adequate near-term liquidity, but down 9% during Q1. |
| Accumulated deficit | $(19.492M) | $(21.140M) | Cumulative losses continue to rise before commercialization. |
Who owns Silo Pharma stock, and how is it governed?
Silo has one common share class with one vote per share, so it lacks a founder-controlled dual-class structure. The preliminary 2026 proxy reported 1,128,610 shares outstanding on June 18, 2026 after the reverse split. Many Ads, seller of the QwikAgents assets, held 140,000 shares, or 12.40%; Intracoastal Capital held 9.99%; and three other investment entities each exceeded 5% under the proxy’s beneficial-ownership calculation.
| Holder / group | Beneficial shares | Reported stake | Source date | Why it matters |
|---|---|---|---|---|
| Many Ads, Inc. | 140,000 | 12.40% | June 18, 2026 proxy record date | Asset seller became the largest disclosed holder. |
| Intracoastal Capital, LLC | 125,962 | 9.99% | June 18, 2026 | Stake largely reflects exercisable warrants and ownership caps. |
| SEG Opportunity Fund LLC | 63,493 | 5.33% | June 18, 2026 | Illustrates financing-linked institutional ownership. |
| Anson Investments Master Fund LP | 63,493 | 5.33% | June 18, 2026 | Reported ownership includes presently exercisable warrants. |
| Directors and executive officers | 41,919 | 3.63% | June 18, 2026 | Management has influence but not voting control. |
Board structure and incentive signals
The preliminary proxy proposed increasing authorized common shares from 6,666,667 to 250,000,000. That flexibility can support financing and acquisitions, but it also expands dilution capacity. Governance analysis should therefore track how the board balances pipeline funding, software expansion, repurchases, and security issuance.
What opportunities could change Silo Pharma’s outlook?
The largest opportunity is successful transition of SPC-15 from preclinical and IND-enabling work into human testing. A cleared IND and first-in-human study would convert the program from a formulation-and-rights story into a clinical asset with measurable safety, pharmacokinetic, and biomarker data. Positive early evidence could improve partner interest and financing terms. A second opportunity is demonstrating that SP-26’s implant produces reliable, controllable ketamine exposure without unacceptable local or systemic safety issues.
Technology diversification can help only if it becomes measurable
QwikAgents could create earlier recurring revenue than the drug pipeline, and the company’s July 2026 announcement that the platform joined AMD’s AI Developer Program may improve technical access or credibility. Yet the strategic benefit depends on disclosed customer count, monthly recurring revenue, churn, hosting cost, and gross margin. Without those metrics, the platform remains optionality rather than a proven cash generator. The company’s official news releases are the most direct source for program and platform updates.
What risks could weaken the Silo Pharma story?
The dominant risk is development failure. None of Silo’s therapeutic candidates has generated approved-product revenue, and preclinical promise may not translate into human safety or efficacy. The company also depends on licensors, research organizations, manufacturers, and academic collaborators; failures in agreements, diligence, intellectual property, or regulatory acceptance could impair a program.
Dilution and strategic sprawl are unusually important
At June 18, 2026, the proxy listed 663,961 shares issuable through presently exercisable warrants and 34,857 through options, both post-split. The July financing added common stock, pre-funded warrants, Series A-3 and A-4 warrants, and placement-agent warrants. Exercises can add cash but expand the share count. Crypto and software spending may also compete with therapeutic priorities and introduce market, cybersecurity, and implementation risks.
| Risk | Financial line affected | Company-specific trigger | What to monitor |
|---|---|---|---|
| Clinical / regulatory failure | R&D asset value and future financing terms | IND delay, safety issue, weak pharmacokinetics, or negative trial data | FDA correspondence, trial starts, and endpoints |
| Financing and dilution | Shares outstanding and per-share value | New equity, pre-funded warrants, or cashless exercises | 8-Ks, warrant exercises, and authorized-share changes |
| License dependency | Pipeline rights and development costs | Missed payments, diligence failures, or changed partner terms | Amendments and milestone obligations |
| Crypto volatility | Other income, liquidity, and asset values | Price declines, impairment, staking, custody, or liquidity events | Carrying value, gains/losses, and concentration |
| AI execution | R&D expense and future software margins | Low adoption, high hosting cost, security failures, or rapid platform obsolescence | Customers, MRR, churn, margin, and uptime |
| Listing risk | Liquidity and financing access | Future noncompliance with Nasdaq criteria | Bid price, equity, and exchange notices |
Why does Silo Pharma matter for valuation?
A conventional DCF built from current revenue is not useful because Silo has no established commercial product economics. Valuation must be scenario-based: probability of development success, launch timing, addressable patients, net pricing, partner economics, spending, and exclusivity for each drug program. QwikAgents requires a separate subscription model using customers, monthly revenue, churn, hosting cost, and sales expense. Crypto and liquid investments belong in the balance-sheet bridge.
| Valuation driver | Base evidence today | Upside signal | Downside signal |
|---|---|---|---|
| SPC-15 probability of success | Pre-IND work and stability progress | IND clearance and acceptable human data | Regulatory delay or weak safety/exposure |
| Time to cash flow | No approved products | Partner-funded development or upfront licensing payment | Self-funded trials with repeated equity issuance |
| Operating burn | $4.661M operating cash use in FY2025 | Lower burn or cost-sharing agreement | Higher clinical, software, or corporate spending |
| Dilution | Large warrant overhang relative to post-split shares | Non-dilutive partnership cash | Additional discounted offerings or cashless exercises |
| QwikAgents value | Disclosed pricing, no reported operating KPIs | Visible MRR, retention, and positive unit economics | No traction or rising hosting and support costs |
Which KPIs should researchers watch next?
What is the key takeaway from Silo Pharma analysis?
Silo is a useful case study in micro-cap biotechnology capital allocation. SPC-15 combines licensed academic research, biomarkers, and targeted intranasal delivery for PTSD, but the company also has no commercial drug sales, recurring losses, financing dependence, licensing obligations, and substantial dilution sensitivity. Crypto assets and AI-agent software may create new revenue paths, yet they also increase execution complexity.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.